Status: Not yet recruiting
Hyaluronidase for Sclerodactyly in Systemic Sclerosis Trial
Translational studies have demonstrated reduced hyaluronidase activity in the skin of patients with systemic sclerosis. It is thought this may contribute to the progressive fibrosis seen in this disease. Several studies have demonstrated that exogenous hyaluronidase is very effective at improving systemic sclerosis associated microstomia. Therefore, this study aims to explore hyaluronidase for systemic sclerosis associated sclerodactyly.
Participants needed: 10
Trial details
Phase: Early Phase 1Age: 18-60Biological sex: AllType: InterventionalSponsor: Medical University of South CarolinaUpdated: Jul 13, 2026Locations: 1
Eligibility criteria
Age ≥18 and <60 years [+3]
Known hypersensitivity to hyaluronidase [+4]